MEF2B and diffuse large B-cell lymphoma: Moreover, MEF2B is the target of heterozygous somatic mutations in 8–18% of diffuse large B-cell lymphoma (DLBCL)14, 15, 16, 13% of follicular lymphoma14 and 3% of mantle cell lymphoma17.